Turning Renal Cell Carcinoma into a Chronic Disease with Targeted Therapies
Author Information
Author(s): Martin Gore, James Larkin
Primary Institution: Royal Marsden Hospital
Hypothesis
Can targeted therapies convert metastatic renal cell carcinoma into a chronic disease?
Conclusion
Targeted agents have significantly improved the prognosis for patients with metastatic renal cell carcinoma and may allow it to be managed as a chronic disease.
Supporting Evidence
- Targeted therapies have improved overall survival rates for patients with metastatic renal cell carcinoma.
- Sunitinib has been shown to double median progression-free survival compared to previous treatments.
- Sequential therapy may help overcome drug resistance in patients with metastatic renal cell carcinoma.
Takeaway
Doctors are finding new medicines that can help people with kidney cancer live longer, and they hope to make it a disease that can be managed over time, like diabetes.
Methodology
This review examines the development and efficacy of targeted agents for managing metastatic renal cell carcinoma and discusses future treatment challenges.
Potential Biases
Potential bias in the selection of studies reviewed and the interpretation of their results.
Limitations
The review does not provide new experimental data but synthesizes existing literature.
Participant Demographics
The review discusses a general population of patients with metastatic renal cell carcinoma, but specific demographics are not provided.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 0.25–0.43
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website